Quote | Cardiol Therapeutics Inc. (NASDAQ:CRDL)
Last: | $2.18 |
---|---|
Change Percent: | 0.0% |
Open: | $2.24 |
Close: | $2.18 |
High: | $2.25 |
Low: | $2.15 |
Volume: | 273,478 |
Last Trade Date Time: | 05/14/2024 03:00:00 am |
News | Cardiol Therapeutics Inc. (NASDAQ:CRDL)
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Fai...
2024-04-02 09:53:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cardiol Therapeutics (NASDAQ: CRDL ) just reported results for the fourth quarter of 2023. Cardiol Therapeutics reported earnings per share of -9 cents. This was above the...
Message Board Posts | Cardiol Therapeutics Inc. (NASDAQ:CRDL)
Subject | By | Source | When |
---|---|---|---|
Market seems to have liked the update today: | 12yearplan | investorshub | 03/29/2023 2:16:48 PM |
https://ih.advfn.com/p.php?pid=staticchart&s=NASDAQ%3ACRDL&p=1&t=17&width=2 | 12yearplan | investorshub | 01/20/2023 4:04:03 PM |
znewcar1: $CRDL 38% v882K c.715 f63,7M H.750 ML.4734 | znewcar1 | investorshangout | 12/10/2022 3:27:53 AM |
Filings says it all - lean and mean: | 12yearplan | investorshub | 11/11/2022 2:33:40 PM |
Yes, screamin' buy at historical lows.. | 12yearplan | investorshub | 11/10/2022 1:51:42 PM |
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Fai...